http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103933569-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965 |
| filingDate | 2013-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103933569-B |
| titleOfInvention | Anti-lung cancer pharmaceutical composition, its application, pill case and package |
| abstract | The invention belongs to the technical field of biology medicine, and relates to an anti-lung cancer pharmaceutical composition, an application, a pill case and a package, the pharmaceutical composition, the pill case and the package contain amiloride with therapeutically effective amount and an epidermal growth factor tyrosine kinase inhibitor EGFR-TKI with therapeutically effective amount which are can be taken as a combined preparation and used in a simultaneous, separating or orderly mode, and also comprises erlotinib and gefitinib but not limited; wherein the mol ratio of amiloride to EGFR-TKI is 500: 1-1: 50. When the pharmaceutical composition, the pill case and the package are used for treating tumor, the drug efficiency which is better than that of EGFR-TKI with individual usage can be obtained, and has curative effect for EGFR-TKI drug resistant tumor due to K-ras mutation. |
| priorityDate | 2013-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 127.